Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.4 EUR | -10.36% | -0.87% | +73.77% |
05-16 | Transcript : NewAmsterdam Pharma Company N.V. - Special Call | |
05-15 | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.77% | 1.71B | |
+8.38% | 114B | |
+10.13% | 104B | |
-11.69% | 22.5B | |
+1.02% | 22.57B | |
-11.14% | 17.95B | |
-41.90% | 16.48B | |
-16.00% | 15.82B | |
+2.28% | 13.55B | |
+20.54% | 10.99B |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- NewAmsterdam Pharma Says Alzheimer's Disease Drug Candidate May Improve Cognitive Function